Gastric Gluten-Degradation Activity of PvP001

NCT ID: NCT03594331

Last Updated: 2019-02-15

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-05-25
• Study Completion Date: 2019-02-06

Brief Summary

This is a single blind, dose escalating, placebo-controlled, crossover study of gluten-degrading drug PvP001 administered to healthy volunteers (age 18-64 years). Subjects will be randomized to one of three groups representing different levels of gluten exposure - low, medium, or high - in a single meal. Within each gluten exposure group, increasing doses of PvP001 (or placebo) will be administered.

Conditions

Digestive System Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

Gluten Exposure Group 1

This group will ingest the drug and then consume a study meal containing a low level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.

Group Type: EXPERIMENTAL

Low-dose PvP001

Intervention Type: DRUG

Low-dose PvP001

Medium-dose PvP001

Intervention Type: DRUG

Medium-dose PvP001

High-dose PvP001

Intervention Type: DRUG

High-dose PvP001

Placebo

Intervention Type: DRUG

100 mL liquid with no drug

Gluten Exposure Group 2

This group will ingest the drug and then consume a study meal containing a medium level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, to the dose of PvP001 and to which visit placebo is given.

Group Type: EXPERIMENTAL

Low-dose PvP001

Intervention Type: DRUG

Low-dose PvP001

Medium-dose PvP001

Intervention Type: DRUG

Medium-dose PvP001

High-dose PvP001

Intervention Type: DRUG

High-dose PvP001

Placebo

Intervention Type: DRUG

100 mL liquid with no drug

Gluten Exposure Group 3

This group will ingest the drug and then consume a study meal containing a high level of gluten. In four separate visits, each subject will be administered low-dose PvP001, medium-dose PvP001, high-dose PvP001 and placebo, with blinding to the dose of PvP001 and to which visit placebo is given.

Group Type: EXPERIMENTAL

Low-dose PvP001

Intervention Type: DRUG

Low-dose PvP001

Medium-dose PvP001

Intervention Type: DRUG

Medium-dose PvP001

High-dose PvP001

Intervention Type: DRUG

High-dose PvP001

Placebo

Intervention Type: DRUG

100 mL liquid with no drug

Interventions

Low-dose PvP001

Low-dose PvP001

Intervention Type: DRUG

Medium-dose PvP001

Medium-dose PvP001

Intervention Type: DRUG

High-dose PvP001

High-dose PvP001

Intervention Type: DRUG

Placebo

100 mL liquid with no drug

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy volunteers;
• Able to maintain a gluten-free diet (GFD) for 24 hours prior to each of visits 1-4;
• Able to abstain from alcohol consumption 72 hours before and 72 hours after each visit;
• Able to tolerate the placement, presence, and manipulation of an oro-gastro-duodenal (OGD) tube;
• Women of child-bearing potential and men whose partners are women of child-bearing potential must be willing to use acceptable birth control for the duration of the study;
• Able to read and understand English;
• Able to provide written informed consent

Exclusion Criteria

• Any condition or abnormality, current or past, that, in the opinion of the investigator, would compromise the safety of the subject, or would interfere with or complicate study procedures or assessments.
• No current or recent (within 14 days prior to each study visit, clinical laboratory testing, and ECG) use of over-the-counter or prescription medications via any route of administration, except for oral contraceptives for birth control (provided they have been used regularly for at least the past 3 months). Other medications used regularly at stable doses may be acceptable at the discretion of the study doctor.
• Current symptoms of congestion, upper respiratory tract infection, or acute illness
• Chronic viral infection or immunodeficiency condition
• Any female who is pregnant, planning to become pregnant during the study, or breast-feeding
• History of intolerance, hypersensitivity, or reaction to wheat or other grains, gluten, or any other food or food ingredient (including an additive or preservative) in the study meal;
• Receipt of an investigational medication within four weeks prior to the screening visit or from the screening visit through the final visit;
• Alcohol consumption >5 drinks/week or any alcohol consumption within the 72 hours prior to each study exposure visit or a positive breathalyzer test result at any study visit;
• Illicit or recreational drug use in the past 12 months or positive urine drug screen at the screening visit;
• History of smoking, nicotine, or tobacco use in the past 12 months;
• History or high risk of noncompliance with treatment or visits.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

PvP Biologics, Inc.

INDUSTRY

Sponsor Role: collaborator

Danielle Kim Turgeon

OTHER

Sponsor Role: lead

Responsible Party

Danielle Kim Turgeon

Professor of Internal Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Danielle Kim Turgeon, MD

Role: PRINCIPAL_INVESTIGATOR

University of Michigan

Locations

Michigan Medicine

Ann Arbor, Michigan, United States

Countries

United States

Other Identifiers

HUM00122254

Identifier Type: -

Identifier Source: org_study_id